The current “production and innovation credit” regime was designed with an objective of spurring productivity growth and promoting innovation. Some believe that this goal has not been met, and it has been suggested that the credit would benefit from being “more calibrated” to address different needs that businesses have.
For instance, one solution put forward would be to provide a hybrid framework under the “production and innovation credit” regime, offering a combination of targeted incentives for different activities during the life journey of each Singapore business.
Read a March 2016 report [PDF 422 KB] prepared by the KPMG member firm in Singapore: Boosting value creation through Budget 2016
Singapore’s research and development (R&D) incentives for the biomedical sector include the productivity and innovation credit that provides a 400% tax deduction on R&D—but subject to a cap of S$400,000 or S$600,000 (approximately U.S. $292,000 or $437,000, respectively).
Singapore also has an “angel investors tax deduction” program that provides a tax deduction for 50% of the investment amount, up to a cap of S$500,000. Concerning both incentives, it has been asserted that the dollar-amount caps are too low to benefit the biomedical sector and the risks associated with R&D in this sector.
Read a March 2016 report [PDF 202 KB] prepared by the KPMG member firm in Singapore: Growing Singapore’s biomedical R&D
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.